NEUN Stock Overview
Manufactures and sells nutritional supplements primarily in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Neurogenesis, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0001 |
| 52 Week High | US$0.0001 |
| 52 Week Low | US$0.0001 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | 0% |
| 3 Year Change | n/a |
| 5 Year Change | -98.51% |
| Change since IPO | -99.99% |
Recent News & Updates
Recent updates
Shareholder Returns
| NEUN | US Personal Products | US Market | |
|---|---|---|---|
| 7D | 0% | 2.3% | 1.2% |
| 1Y | 0% | -28.1% | 23.7% |
Return vs Industry: NEUN exceeded the US Personal Products industry which returned -29.6% over the past year.
Return vs Market: NEUN underperformed the US Market which returned 22.4% over the past year.
Price Volatility
| NEUN volatility | |
|---|---|
| NEUN Average Weekly Movement | n/a |
| Personal Products Industry Average Movement | 7.8% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 18.0% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: NEUN's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine NEUN's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | n/a | Tal Gilat | www.neurogenesis.com |
Neurogenesis, Inc. manufactures and sells nutritional supplements primarily in the United States. The company offers NeuBecalm’d, a nutritional supplement to reduce the effects of acute and chronic stress factors; NeuBecalm'd Chewables that reduces the effects of stress and enhance focus; and NeuRecover, a nutritional support for the natural replenishment of neurotransmitters depleted by the long-term use of alcohol. It also provides NeuReplenish, a nutritional support for restoring and rebuilding healthy brain chemistry that has been altered or depleted by the long-term use of chemical stimulants; NeuRelieve, a nutritional support for restoring and rebuilding healthy brain chemistry that has been altered or depleted by the long-term use of antianxiety drugs, and to be used in conjunction with professional support during the tapering process; and NeuSlim, which aids in the reduction of cravings (or urges) for simple carbohydrates, to reduce excessive appetite in general, and to assist in healthy moderation of nutritional needs.
Neurogenesis, Inc. Fundamentals Summary
| NEUN fundamental statistics | |
|---|---|
| Market cap | US$8.23k |
| Earnings (TTM) | -US$9.60k |
| Revenue (TTM) | US$1.07m |
0.0x
P/S Ratio0.0x
P/E RatioIs NEUN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NEUN income statement (TTM) | |
|---|---|
| Revenue | US$1.07m |
| Cost of Revenue | US$217.94k |
| Gross Profit | US$851.52k |
| Other Expenses | US$861.12k |
| Earnings | -US$9.60k |
Last Reported Earnings
Sep 30, 2007
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did NEUN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/19 10:14 |
| End of Day Share Price | 2025/01/17 00:00 |
| Earnings | 2007/09/30 |
| Annual Earnings | 2006/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Neurogenesis, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.